Sionna Therapeutics, Inc. - Common Stock, $0.001 par value per share (SION)

CUSIP: 829401108

Q3 2026 13F Holders as of 30 Sep 2026

Holder snapshot 6 signals
Share change
+1,078,580
SEC-reported price per share
$5.26
Number of holders
8
Value change
+$5,672,550
Number of buys
7
Number of sells
1
Security identity Names, identifiers, and filing context for this profile. 1 source field
Shares outstanding
45,288,063

Security key

829401108

Report period

Q3 2026

Institutions

8

Top holders

9

Ownership snapshot

Top reported holders of SION - Sionna Therapeutics, Inc. - Common Stock, $0.001 par value per share (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
TPG GP A, LLC
Disclosed value leader
RA CAPITAL MANAGEMENT, L.P.
Comparable rows
8/15
Latest evidence
17 Sep 2026
13F 13D/G 3/4/5 Lead comparable stake: 15% 7 rows are not safely comparable across share classes. 13D/G row: TPG GP A, LLC Showing 1-6 of 15 holder rows.

Quick read

TPG GP A, LLC leads the comparable SEC ownership view at 15%.

8 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens TPG GP A, LLC's linked filing trail.
Comparable ownership Top 5
TPG GP A, LLC 15%
RA CAPITAL MANAGEMENT, L.P. 14%
VIKING GLOBAL INVESTORS LP 7.1%
ORBIMED ADVISORS LLC 6.6%
Enavate Sciences GP, LLC 5.6%

Ownership % is shown only when SEC disclosures are safely comparable across share classes.

Detailed SEC evidence table Showing 1-6 of 15 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
TPG GP A, LLC
13F 13D/G 3/4/5
Company · 10%+ Owner
15%
Reported 13D/G · 10 Feb 2025
$285,713,378
6,494,962 shares
— 30 Jun 2026
RA CAPITAL MANAGEMENT, L.P.
13F 13D/G 3/4/5
Company · Director, 10%+ Owner
14%
Reported 13D/G · 17 Sep 2026
$435,722,930
9,905,045 shares
— 30 Jun 2026
VIKING GLOBAL INVESTORS LP
13F 13D/G
Company
7.1%
Reported 13D/G · 31 Mar 2026
$140,556,012
3,195,181 shares
— 30 Jun 2026
ORBIMED ADVISORS LLC
13D/G 3/4/5 13F
Director · Company
6.6%
Reported 13D/G · 15 Apr 2026
$118,970,633
2,967,722 shares
-$29,554,504 15 Apr 2026
Enavate Sciences GP, LLC
13F 13D/G
Company
5.6%
Reported 13D/G · 10 Feb 2025
$109,008,540
2,478,030 shares
— 30 Jun 2026
Atlas Venture Fund XI, L.P.
13D/G 3/4/5
10%+ Owner
5.4%
Reported 13D/G · 16 Oct 2025
$74,744,824
2,382,495 shares
-$15,805,403 16 Oct 2025
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q3 2026

Investor-level positions for this CUSIP, loaded as an interactive table.

Institutions
8
Shares
1,079,041
Rows available
8
Investor Option Weight % Change % SEC-reported value * Price Shares Share Change Activity Report Period

* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Compare Q3 2026 vs Q1 2026 Across Filers

Q1 2026 holders
121
Q3 2026 holders
8
Holder diff
-113
Investor Q1 2026 Shares Q3 2026 Shares Share Diff Share Chg % Q1 2026 value Q3 2026 value Value change Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .